Beilei He
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.
Journal: Nature communications
Published: February 28, 2025
Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 27, 2024
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
Journal: Journal for immunotherapy of cancer
Published: April 26, 2024
Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 22, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 05, 2021
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 04, 2019
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Journal: Scientific reports
Published: July 23, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026